LYEL:NASDAQ
Lyell Immunopharma Inc
US$7,99
0,00%
(0,00) 1D
14 ຕ.ລ., 16 ໂມງ 0 ນາທີ 00 ວິນາທີ GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LYEL...
Mkt. cap
195,80 ລ້ານ
Avg. vol.
149,51 ພັນ
Volume
35,00
52-wk high
US$45,00
52-wk low
US$7,20
EPS
US$-12,01
Beta
-0,03
Shares outstanding
24,50 ລ້ານ
No. of employees
161
Mkt. cap
195,80 ລ້ານ
Avg. vol.
149,51 ພັນ
Volume
35,00
52-wk high
US$45,00
52-wk low
US$7,20
EPS
US$-12,01
Beta
-0,03
Shares outstanding
24,50 ລ້ານ
No. of employees
161
News stories
From web sources and news partners
Investing.com Nigeria
·
1 ມື້ກ່ອນ
Lyell Immunopharma CMO sells $3,641 in shares for tax withholding By Investing.com
Profile
Lyell Immunopharma, Inc. is an American clinical-stage biopharmaceutical company headquartered in San Francisco, California. Founded in 2018, the company develops next-generation cell therapies, including CAR T cell, using technologies intended to improve T-cell persistence, function, and resistance to exhaustion. Its pipeline includes therapies being developed for hematologic malignancies and solid tumors. Wikipedia
About Lyell Immunopharma Inc
CEO-
Employees161
Founded2018
HeadquartersSouth San Francisco, ແຄລິຟໍເນຍ, ສະຫະລັດ
SectorBiotechnology
Websitelyell.com